Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 90 of 228 for:    yeast

Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02740777
Recruitment Status : Unknown
Verified March 2017 by Shanghai Zerun Biotechnology Co.,Ltd.
Recruitment status was:  Recruiting
First Posted : April 15, 2016
Last Update Posted : March 8, 2017
Sponsor:
Collaborator:
Guangxi Center for Disease Control and Prevention
Information provided by (Responsible Party):
Shanghai Zerun Biotechnology Co.,Ltd

Brief Summary:
To evaluate the immune non-inferiority, as measured by antibody responses, of a 2-dose immunization schedule (0, 6 months) of recombinant human papillomavirus virus-like particle vaccine (type 16 and 18 L1 proteins, yeast) (hereinafter referred as HPV-2 vaccine) in adolescent females aged 9 to 14 years in comparison to 3-dose immunization schedule (0, 2, 6 months) in young females aged 18 to 26 years.

Condition or disease Intervention/treatment Phase
Human Papillomavirus Cervical Intraepithelial Neoplasia Persistent Infection Biological: HPV-16/18 vaccine Phase 2

Detailed Description:

The study plans to enroll 600 adolescent females aged 9 to 14 years and 300 adult females aged 18 to 26 years. The adolescents will be divided into two cohorts, 300 each, receiving either a 2-dose (0, 6 months) immunization schedule or a 3-dose (0, 2, 6 months) immunization schedule. The adult female group will receive a 3-dose (0, 2, 6 months) immunization schedule.

Each subject shall be administrated with the studied vaccine according to either 2-dose or 3-dose schedule as above. Immediate reactions occurred during 30 minutes after each inoculation, all the local and systematic reactions occurred from 0 to 7 days after each inoculation will be recorded. All the adverse events (AEs) occurred from the first dose of administration to 1 month after the final dose of administration, as well as all the serious adverse events (SAEs) occurred from the first dose of administration to 6 months after the final dose of administration will be collected. Blood samples will be collected at day 0 (prior to immunization) , month 6 (prior to the last injection) , month 7, month 12, month 24, and month 36. All the blood samples will be tested HPV 16- and HPV 18-specific antibody titers.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 900 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years
Study Start Date : February 2016
Actual Primary Completion Date : November 2016
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 2-dose adolescent
300 adolescent girl will receive a two-dose schedule (0 day, 6 months) immunization of HPV-16/18 vaccine.
Biological: HPV-16/18 vaccine
HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.

Experimental: 3-dose adolescent
300 adolescent girl will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
Biological: HPV-16/18 vaccine
HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.

Experimental: 3-dose adult
300 adult women will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
Biological: HPV-16/18 vaccine
HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.




Primary Outcome Measures :
  1. HPV-16 and HPV-18 antibody titers (GMT) [ Time Frame: one month after the final injection ]
    Compare the HPV-16 and HPV-18 specific antibody titers (GMT) between the 2-dose immunization schedule (0, 6 months) in adolescent females aged 9 to 14 years and the 3-dose immunization schedule (0, 2, 6 months) in young females aged 18 to 26 years.


Secondary Outcome Measures :
  1. HPV-16 and HPV-18 antibody titers (GMT) and the seroconversion rate [ Time Frame: 30 months after the final injection ]
    Compare the immunogenicity between the 2-dose (0, 6 months) and the 3-dose (0, 2, 6 months) immunization schedules in adolescent females aged 9-14 years, on the basis of: 1) antibody titers (GMT) and the seroconversion rate at one month after the final injection, 2) antibody titer persistence and 3) antibody titers at a steady status.

  2. Local and systemic adverse events (AEs) [ Time Frame: 6 months after the final injection ]
    Evaluate all local and systemic adverse events (AEs) occurred within 7 days after each inoculation, at one month and 6 month after the whole immunization



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   9 Years to 24 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Adult group:

  • 18-26 healthy female
  • enable to provide an legal identification
  • have the ability to understand and sign the Informed Consent Form
  • aren't pregnant and do not have pregnancy plan within the 7 months after the first injection
  • used effective contraceptive method from the last menstruation, and agreed to avoid sexual activity without effective contraceptive method within the 15 days after injection

Adolescent group:

  • 9-14 healthy female
  • enable to provide an legal identification
  • guardians have the ability to understand the Informed Consent Form, and both participant and guardian agreed to sign the Form (in case of unable to sign, the participant can use fingerprint as signature)

Exclusion Criteria:

  • History of HPV infection
  • Previous administration of any HPV vaccine
  • History of severe allergic reaction requiring medical intervention (such as oral and throat swelling, difficulty breathing, hypotension or shock)
  • History of allergic to vaccine, or to any ingredient of vaccine.
  • History of epilepsy, seizures or convulsions, or family history of mental illness
  • Subjects are immunocompromised or have been diagnosed as suffering from congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation (JRA), inflammatory bowel disease or other autoimmune diseases, administration of immunosuppressants with six months prior to the first vaccine dose.
  • History of asthma, thyroidectomy, angioneurotic edema, diabetes or malignant
  • Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy
  • Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency, coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder
  • Acute disease or chronic disease acute exacerbation 7 days prior to vaccination
  • Administration of immunoglobulins and/or any blood products within 3 months, or administration of any live attenuated vaccine within 28 days, or administration of any subunit or inactivated vaccines within 14 days.
  • Fever or axillary temperature> 37.0 °C before vaccination
  • During menstrual period, breastfeeding, pregnancy(pregnancy test positive), or planned pregnant within 7 month
  • History of hypertension, physical examination systolic blood pressure> 150mmHg and/or diastolic blood pressure> 100mmHg
  • Abnormal laboratory tests parameters
  • Any clinical significant disease or findings during study screening that, in the opinion of the Investigator may interfere with the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02740777


Contacts
Layout table for location contacts
Contact: Zhaojun Mo +86 771-2518780 mozhj@126.com

Locations
Layout table for location information
China, Guangxi
Hezhou Center for Disease Prevention and Control Recruiting
Hezhou, Guangxi, China, 542899
Contact: Youshou Li    086-774-5139230    hzsswzp@163.com   
Zhongshan Center for Disease Prevention and Control Recruiting
Zhongshan, Guangxi, China, 542699
Contact: Guide Nong    086-13321645288    zscdcxmb8989268@163.com   
Sponsors and Collaborators
Shanghai Zerun Biotechnology Co.,Ltd
Guangxi Center for Disease Control and Prevention
Investigators
Layout table for investigator information
Principal Investigator: Zhaojun Mo Guangxi Center for Disease Prevention and Control(GXCDC)

Layout table for additonal information
Responsible Party: Shanghai Zerun Biotechnology Co.,Ltd
ClinicalTrials.gov Identifier: NCT02740777     History of Changes
Other Study ID Numbers: 311-HPV-1004
First Posted: April 15, 2016    Key Record Dates
Last Update Posted: March 8, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cervical Intraepithelial Neoplasia
Neoplasms
Carcinoma in Situ
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Vaccines
Immunologic Factors
Physiological Effects of Drugs